Takeda Pharmaceutical Company
|Takeda Yakuhin Kōgyō kabushiki gaisha|
|Formerly||Chobei Takeda & Co., Ltd. (1925–1943)|
Takeda Pharmaceutical Industries, Ltd. (English name only 1943–1961)
Takeda Chemical Industries, Ltd. (English name only 1961–2004)
|Founded||Doshomachi, Osaka, Japan (12 June 1781)|
|Founder||Chobei Takeda I|
(Chairman of the Board)
(President & CEO)
|Revenue||¥1,770,531 million (FY 2018)[* 1]|
|¥241,789 million (FY 2018)[* 1]|
|¥186,886 million (FY 2012)[* 1]|
|Total assets||¥4,106,463 billion (FY 2018)[* 1]|
|Total equity||¥1,997,424 billion (FY 2018)[* 1]|
Number of employees
|Footnotes / references|
The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
This section may be in need of reorganization to comply with Wikipedia's layout guidelines. (October 2021)
Founding and initial acquisitions (1781-2010)
Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925.
One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999.
In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million.
In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In April, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
Further expansion and research (2011-present)
In September 2011, Takeda acquired Nycomed for €9.6 billion.
In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million. In June, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million.
In September 2014, Takeda announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million. On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
In 2015, Takeda sold its respiratory drugs business to AstraZeneca for $575 million (about £383 million), which included roflumilast and ciclesonide. On November, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
In December 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.
In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.
In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million ($632 million).
In January 2019, Takeda acquired Shire for more than US$50 billion. In October, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million.
In January 2020, Takeda announced a research partnership with the Massachusetts Institute of Technology (MIT) to advance discoveries in artificial intelligence and health. The MIT-Takeda Program is housed in the MIT Jameel Clinic, and is led by Professor James J. Collins, with a steering committee led by Professor Anantha P. Chandrakasan, dean of the MIT School of Engineering, and Anne Heatherington, senior vice president and head of Data Sciences Institute (DSI) at Takeda. In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million.
In March 2021, the company announced it would acquire Maverick Therapeutics, Inc. and its two major programs TAK-186 (MVC-101) in trials for the treatment of EGFR-expressing tumours and TAK-280 (MVC-280) for use in the treatment of patients with B7H3-expressing tumors. In October, they acquired GammaDelta Therapeutics and its gamma delta (γδ) T cell immunotherapy programme.
In January 2022, Takeda announced it would exercise its option to acquire Adaptate Biotherapeutics and its antibody-based γδ T cell technology, reuniting Adaptate and its former parent company, GammaDelta Therapeutics, in a single organisation. In December of the same year, the company announced it would acquire Nimbus Lakshmi, Inc. and its lead compound NDI-034858 which is an allosteric TYK2 inhibitor, from Nimbus Therapeutics, LLC for up to $6 billion.
TAP Pharmaceuticals (1977-2008)
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals Takeda and Abbott launched blockbuster drugs Lupron (leuprorelin), in 1985, then Prevacid (lansoprazole), in 1995.
In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and state medicare fraud. TAP was fined $875 million, then reported as the largest pharmaceutical settlement in history.
In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.
- Takeda Pharmaceutical Company (Est. 1781)
- Syrrx (Acq 2005)
- Millennium Pharmaceuticals (Acq 2008)
- COR Therapeutics (Acq 2002)
- Cambridge Discovery Chemistry (Acq 2000)
- Leukosite (Acq 1999)
- Nycomed (Acq 2011)
- Altana Pharma (Pharmaceuticals div, Acq 2007)
- Bradley Pharmaceuticals (Acq 2007)
- URL Pharma (Acq 2012)
- Multilaba (Acq 2012)
- Cerevance (Neuroscience div, Spun off 2016)
- Ariad Pharmaceuticals (Acq 2017)
- TiGenix (Acq 2018)
- Shire plc (Founded 1986, Acq 2019)
- Pharmavene (Acq 1997)
- Richwood Pharmaceutical Company (Acq 1997)
- Biochem Canada (Acq 2001)
- Transkaryotic Therapeutics (Acq 2005)
- New River Pharmaceuticals Inc (Acq 2007)
- Jerini (Acq 2008)
- Movetis (Acq 2012)
- Advanced BioHealing (Acq 2011)
- FerroKin BioSciences (Acq 2012)
- Lotus Tissue Repair, Inc (Acq 2013)
- Premacure AB (Acq 2013)
- SARcode Bioscience Inc (Acq 2013)
- ViroPharma (Founded 1994, Acq 2013)
- Lev Pharmaceuticals (Acq 2008)
- Fibrotech (Acq 2014)
- Lumena (Acq 2014)
- NPS Pharmaceuticals (Acq 2015)
- Meritage Pharma (Acq 2015)
- Foresight Biotherapeutics (Acq 2015)
- Dyax (Acq 2015)
- Baxalta (Acq 2016)
- PvP Biologics, Inc. (Acq 2020)
- Maverick Therapeutics, Inc. (Acq 2021)
- GammaDelta Therapeutics (Acq 2021)
- Adaptate Biotherapeutics (Acq 2022)
- Nimbus Lakshmi, Inc. (Acq 2022)
In May 2019, Takeda sold its Xiidra dry-eye drug business to Novartis for $5.3 billion, $3.4 billion upfront and up-to $1.9 billion in sales milestones.
In November 2019, Takeda entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan to Stada Arzneimittel for $660 million.
In June 2020, Takeda announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea's Celltrion in a deal worth $278 million.
Also in 2020, Takeda sold TachoSil to Corza Health, Inc. for €350 million.
Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Cambridge, Massachusetts, and all Global Operations outside Japan and the U.K. are based in Opfikon (Zurich), Switzerland. The company maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.
In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that pioglitazone was responsible for giving them bladder cancer. The company said the decision is expected to resolve the “vast majority” of these cases. Takeda will put the money into a settlement fund if 95 percent of plaintiffs agree to the accord, according to which each claimant would get an average $267,000. However, the exact amount for each plaintiff will be evaluated based on cumulative dosage, extent of injuries and history of smoking. In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine, but the amount was later reduced to $26 million by a judge who deemed the charge excessive.
Takeda is a corporate partner of Human Rights Campaign, a large LGBT advocacy organization.
- ^ a b "Company Facts | Takeda". www.takeda.com.
- ^ "The History of Takeda – 1781 to 1944 | Takeda".
- ^ Chris Gallagher (2015-03-15). Muralikumar Anantharaman (ed.). "Japan drugmaker Takeda says Christophe Weber to become CEO April 1". Reuters. Retrieved 2015-04-20.
- ^ a b c "Share Data | Takeda".
- ^ "Working at Takeda Pharmaceuticals NA".
- ^ "Takeda offers early retirement to workers as young as 30". Nikkei Asia.
- ^ "Financial Results for Fiscal 2012" (PDF). Takeda Pharmaceutical Company Limited. 2013-05-09. Retrieved 2013-06-13.
- ^ "FAQ." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."
- ^ "Overview." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"
- ^ "100 Best Companies to Work For 2012". Fortune. 2012-02-06. Retrieved 2018-03-29.
- ^ "Christophe Weber". Takeda.
- ^ Du, Lisa (2018-12-12). "Daring Deal by French CEO Sets Japan's Takeda on Global Path". Bloomberg.com. Retrieved 2020-02-20.
- ^ "Immediate Actos Appeal Will Resolve Uncertainty, Takeda Says". news.bloomberglaw.com. Retrieved 2020-02-20.
- ^ "Japan's Takeda to Acquire Syrrx". Los Angeles Times. 2005-02-08. Retrieved 2020-02-20.
- ^ "Takeda, Amgen in exclusive tie-up for Japanese market". MarketWatch. 2008-02-04. Retrieved 2010-09-18.
- ^ a b "Takeda to buy Millennium Pharma for $8.8 billion". Reuters. 2008-04-10. Retrieved 2020-02-20.
- ^ "Alnylam Signs Potential $1B RNAi Agreement with Takeda". bioworld.com. Retrieved 2020-02-20.
- ^ Dealbook (2011-05-19). "Takeda to Buy Nycomed for $13.7 Billion". DealBook. Retrieved 2020-02-20.
- ^ Hirschler, Ben (2012-05-25). "Farmacêutica Takeda comprará Multilab por até R$ 540 mi". Grupo Abril (in Portuguese). Exame. Retrieved 2013-01-27.
- ^ "Takeda to acquire URL Pharma for $800m". 11 April 2012. Retrieved 2020-02-20.
- ^ "Takeda, BioMotiv Launch $25M Drug Development Partnership". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-26. Retrieved 2015-04-23.
- ^ "Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-30. Retrieved 2015-04-23.
- ^ Julia Bradshaw for The Daily Telegraph, 16 December 2015. AstraZeneca to buy Takeda's lung business for £383m.Accessed: 17 December 2015.
- ^ "Ninlaro (ixazomib) FDA Approval History". Drugs.com. Retrieved 2020-02-20.
- ^ "Takeda Spins Out Research Team into Neuroscience Startup". 2016-12-02.
- ^ "Takeda to Acquire ARIAD Pharmaceuticals for $5.2B". 2017-01-09.
- ^ "Takeda to Acquire TiGenix for €520M". 2018-01-05.
- ^ Du, Lisa; Takahashi, Maiko (8 May 2018). "Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire". Bloomberg. Retrieved 6 July 2019.
- ^ Philippidis, Alex (1 July 2019). "Top 10 M&A Deasl of January—June 2019". Genetic Engineering & Biotechnology News.
And it didn't include earlier-announced deals completed in 2019, such as Takeda Pharmaceutical's £46 billion ($58.6 billion) purchase of Shire.
- ^ "Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino". Reuters. 2019-10-15. Retrieved 2019-10-15.
- ^ "Takeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino". FiercePharma. 15 October 2019. Retrieved 2019-10-15.
- ^ "MIT School of Engineering and Takeda join to advance research in artificial intelligence and health". MIT News | Massachusetts Institute of Technology. Retrieved 2020-11-13.
- ^ analytica, TOKYO (2020-01-07). "武田薬品とMITがAI研究を推進するプログラムを発表 | 医療とAIのニュース・最新記事 - The Medical AI Times". The AI Times (in Japanese). Retrieved 2020-11-13.
- ^ "MIT, Takeda collaborate on new healthcare AI applications". Healthcare IT News. 2020-01-06. Retrieved 2020-11-13.
- ^ "Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD". BioSpace. Retrieved 2020-03-03.
- ^ "Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio". BioSpace.
- ^ "Takeda Snaps up Partner GammaDelta to Bolster Oncology Pipeline".
- ^ "Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors". BioSpace.
- ^ "Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year". BioSpace.
- ^ "Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors". BioSpace.
- ^ "Takeda to Acquire Nimbus Therapeutics' Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases". BioSpace.
- ^ "Takeda Bets $4B Upfront on Nimbus' TYK2 Inhibitor". BioSpace.
- ^ "Takeda shrinks its Deerfield workforce, as it adds in Boston". Crain's Chicago Business. 2017-07-18. Retrieved 2020-02-20.
- ^ Japson, Bruce (Apr 29, 2001). "The Lupron loophole: Cancer drug strikes it rich". Chicago tribune. Retrieved 19 June 2021.
- ^ "Takeda Pharmaceutical to Pay Abbott Laboratories up to $1.5B in Venture Split". FierceBiotech. 20 March 2008. Retrieved 2020-02-20.
- ^ Petersen, Melody (Oct 4, 2001). "2 Drug Makers to Pay $875 Million to Settle Fraud Case". The New York Times. Retrieved June 19, 2021.
- ^ "Press Release: TAP Pharmaceutical Products Inc. and Seven Others Charged with Health Care Crimes". US Department of Justice. Oct 3, 2001. Retrieved June 19, 2021.
- ^ "Abbott, Takeda to end joint venture". Crain's Chicago Business. 2008-03-19. Retrieved 2020-02-20.
- ^ a b Wang, Shirley S. (2008-03-20). "Abbott, Takeda to End Joint Venture". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-02-20.
- ^ Marrazzo, Amanda (2008-05-15). "Featured Articles From The Chicago Tribune". Archives.chicagotribune.com. Retrieved 2010-09-18.
- ^ "Novartis to buy Takeda's eyedrop unit for $5.3bn". Nikkei Asian Review. Retrieved 2020-06-12.
- ^ a b "Takeda continues post-Shire selloff, inching closer to $10B goal". Endpoints News. Retrieved 2020-06-12.
- ^ "Takeda sells Russian assets in $660m deal to cut Shire debt". Nikkei Asian Review. Retrieved 2020-06-12.
- ^ "Takeda sells 18 drugs to South Korea's Celltrion in $278m deal". Nikkei Asian Review. Retrieved 2020-06-12.
- ^ "BRIEF-Takeda Pharmaceutical Enters Into Agreement To Divest Portfolio Of Select Non-Core OTC And Prescription Pharmaceutical Products". Reuters. 2020-06-11. Retrieved 2020-06-12.
- ^ "Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD | Financial Post". Financialpost. 2020-06-11. Retrieved 2020-06-12.
- ^ "Takeda to Divest TachoSil® to Corza Health for €350 Million". www.takeda.com. Retrieved 2023-04-09.
- ^ "Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos". The New York Times. 29 April 2015.
- ^ Feeley, Jef; Matsuyama, Kanoko (9 April 2014). "Takeda, Lilly Jury Awards $9 Billion Over Actos Risks". bloomberg.com.
- ^ "Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit Over Cancer Risk Allegations". International Business Times. 29 April 2015.
- ^ "Corporate Partners". Human Rights Campaign. Archived from the original on 2022-07-14. Retrieved 2022-07-14.
- Media related to Takeda Pharmaceutical Company at Wikimedia Commons
- Official website
- TOPIX 100
- Takeda Pharmaceutical Company
- Companies listed on the Tokyo Stock Exchange
- Companies listed on the Fukuoka Stock Exchange
- Companies listed on the Nagoya Stock Exchange
- Companies listed on the New York Stock Exchange
- Japanese companies established in 1781
- Manufacturing companies based in Osaka
- Multinational companies headquartered in Japan
- Orphan drug companies
- Pharmaceutical companies established in 1781
- Pharmaceutical companies of Japan
- 1940s initial public offerings